Antibody data
- Antibody Data
- Antigen structure
- References [131]
- Comments [0]
- Validations
- Western blot [3]
- Immunohistochemistry [2]
- Flow cytometry [2]
- Other assay [9]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-13105 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ErbB2 (HER-2) Monoclonal Antibody (e2-4001)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA5-13105 targets HER-2 in IHC, ICC/IF, IP, FACS and WB applications and shows reactivity with human, mouse, and rat samples.
- Antibody clone number
- e2-4001
- Concentration
- 400 µg/mL
Submitted references Establishment of a New Cell Line of Canine Mammary Tumor CMT-1026.
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer.
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy.
NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer.
Interactome Mapping Uncovers a General Role for Numb in Protein Kinase Regulation.
Profiling protein expression in circulating tumour cells using microfluidic western blotting.
Integrated Molecular Characterization of Uterine Carcinosarcoma.
Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling.
A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines.
High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.
Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations.
Micropapillary component in gastric adenocarcinoma: an aggressive variant associated with poor prognosis.
Molecular architecture of the ErbB2 extracellular domain homodimer.
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.
A cell-based screening system for influenza A viral RNA transcription/replication inhibitors.
Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.
NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity.
Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases.
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
SGK3 is associated with estrogen receptor expression in breast cancer.
Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival.
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype.
Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast.
Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.
Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine.
HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.
Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling.
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.
Immunohistochemical characterization of subtypes of male breast carcinoma.
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy.
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.
Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.
Leptin augments proliferation of breast cancer cells via transactivation of HER2.
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
Prognostic significance of HER-2 status in women with inflammatory breast cancer.
Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent.
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.
Lipid raft localization of ErbB2 in vestibular schwannoma and schwann cells.
Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44.
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
Loss of annexin A1 expression in breast cancer progression.
Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF.
Primary neuroendocrine carcinoma of the breast: a case report.
Primary neuroendocrine carcinoma of the breast: a case report.
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer.
Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.
Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications.
An acetylation site in the middle domain of Hsp90 regulates chaperone function.
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis.
[An analysis of genetic transmission in a father and son with osteosarcoma].
MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC).
Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2.
Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker.
Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker.
Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer.
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases.
Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry.
Decorin prevents metastatic spreading of breast cancer.
Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells.
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2.
Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK.
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors.
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures.
Role of ErbB2 in Corneal Epithelial Wound Healing.
Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions.
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells.
Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Metalloproteinases stimulate ErbB-dependent ERK signaling in human skin organ culture.
Differential cytoskeletal association of ErbB1 and ErbB2 during keratinocyte differentiation.
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
Mei C, Xin L, Liu Y, Lin J, Xian H, Zhang X, Hu W, Xia Z, Wang H, Lyu Y
Frontiers in veterinary science 2021;8:744032
Frontiers in veterinary science 2021;8:744032
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer.
Punturi NB, Seker S, Devarakonda V, Mazumder A, Kalra R, Chen CH, Li S, Primeau T, Ellis MJ, Kavuri SM, Haricharan S
Nature communications 2021 May 19;12(1):2940
Nature communications 2021 May 19;12(1):2940
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy.
Arulanandam R, Taha Z, Garcia V, Selman M, Chen A, Varette O, Jirovec A, Sutherland K, Macdonald E, Tzelepis F, Birdi H, Alluqmani N, Landry A, Bergeron A, Vanderhyden B, Diallo JS
Communications biology 2020 May 22;3(1):254
Communications biology 2020 May 22;3(1):254
NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer.
Dischinger PS, Tovar EA, Essenburg CJ, Madaj ZB, Gardner EE, Callaghan ME, Turner AN, Challa AK, Kempston T, Eagleson B, Kesterson RA, Bronson RT, Bowman MJ, Graveel CR, Steensma MR
NPJ breast cancer 2018;4:29
NPJ breast cancer 2018;4:29
Interactome Mapping Uncovers a General Role for Numb in Protein Kinase Regulation.
Wei R, Kaneko T, Liu X, Liu H, Li L, Voss C, Liu E, He N, Li SS
Molecular & cellular proteomics : MCP 2018 Nov;17(11):2216-2228
Molecular & cellular proteomics : MCP 2018 Nov;17(11):2216-2228
Profiling protein expression in circulating tumour cells using microfluidic western blotting.
Sinkala E, Sollier-Christen E, Renier C, Rosàs-Canyelles E, Che J, Heirich K, Duncombe TA, Vlassakis J, Yamauchi KA, Huang H, Jeffrey SS, Herr AE
Nature communications 2017 Mar 23;8:14622
Nature communications 2017 Mar 23;8:14622
Integrated Molecular Characterization of Uterine Carcinosarcoma.
Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB, Cancer Genome Atlas Research Network, Weinstein JN, Zhang J, Akbani R, Levine DA
Cancer cell 2017 Mar 13;31(3):411-423
Cancer cell 2017 Mar 13;31(3):411-423
Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling.
Hill SM, Nesser NK, Johnson-Camacho K, Jeffress M, Johnson A, Boniface C, Spencer SE, Lu Y, Heiser LM, Lawrence Y, Pande NT, Korkola JE, Gray JW, Mills GB, Mukherjee S, Spellman PT
Cell systems 2017 Jan 25;4(1):73-83.e10
Cell systems 2017 Jan 25;4(1):73-83.e10
A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines.
Sochaj-Gregorczyk AM, Serwotka-Suszczak AM, Otlewski J
Journal of immunotherapy (Hagerstown, Md. : 1997) 2016 Jul-Aug;39(6):223-32
Journal of immunotherapy (Hagerstown, Md. : 1997) 2016 Jul-Aug;39(6):223-32
High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.
Liu H, Du L, Wang R, Wei C, Liu B, Zhu L, Liu P, Liu Q, Li J, Lu SL, Xiao J
Oncotarget 2015 May 10;6(13):11477-91
Oncotarget 2015 May 10;6(13):11477-91
Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA, Kaufman PA, Huang W, Krekow L, Savin M, Lawler WE, Zrada S, Starr A, Einhorn H, Schwartzberg LS, Adams JW, Lie Y, Paquet AC, Sperinde J, Haddad M, Anderson S, Brigino M, Pesano R, Bates MP, Weidler J, Bosserman L
Breast cancer research : BCR 2015 Mar 18;17(1):41
Breast cancer research : BCR 2015 Mar 18;17(1):41
Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations.
Demicco EG, Wani K, Fox PS, Bassett RL, Young ED, Lev D, Aldape KD, Lazar AJ, Wang WL
Human pathology 2015 Jul;46(7):1015-26
Human pathology 2015 Jul;46(7):1015-26
Micropapillary component in gastric adenocarcinoma: an aggressive variant associated with poor prognosis.
Zhang Q, Ming J, Zhang S, Li B, Yin L, Qiu X
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2015 Jan;18(1):93-9
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2015 Jan;18(1):93-9
Molecular architecture of the ErbB2 extracellular domain homodimer.
Hu S, Sun Y, Meng Y, Wang X, Yang W, Fu W, Guo H, Qian W, Hou S, Li B, Rao Z, Lou Z, Guo Y
Oncotarget 2015 Jan 30;6(3):1695-706
Oncotarget 2015 Jan 30;6(3):1695-706
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD, Timme S, Braun JA, Gudernatsch V, Schöpflin A, Bogatyreva L, Geddert H, Faller G, Klimstra D, Tang L, Hauschke D, Werner M, Lassmann S
International journal of cancer 2014 Oct 1;135(7):1517-30
International journal of cancer 2014 Oct 1;135(7):1517-30
erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.
Steinkamp MP, Low-Nam ST, Yang S, Lidke KA, Lidke DS, Wilson BS
Molecular and cellular biology 2014 Mar;34(6):965-77
Molecular and cellular biology 2014 Mar;34(6):965-77
A cell-based screening system for influenza A viral RNA transcription/replication inhibitors.
Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, Furuta Y, Horimoto T, Peters NR, Hoffmann FM, Kawaoka Y
Scientific reports 2013;3:1106
Scientific reports 2013;3:1106
Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
Sak MM, Szymanska M, Bertelsen V, Hasmann M, Madshus IH, Stang E
Carcinogenesis 2013 Sep;34(9):2031-8
Carcinogenesis 2013 Sep;34(9):2031-8
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Falchook GS, Moulder SL, Wheler JJ, Jiang Y, Bastida CC, Kurzrock R
Annals of oncology : official journal of the European Society for Medical Oncology 2013 Dec;24(12):3004-11
Annals of oncology : official journal of the European Society for Medical Oncology 2013 Dec;24(12):3004-11
Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MT, Bastien RR, Boucher KM, Young E, Iwamoto T, Pusztai L
The oncologist 2012;17(4):492-8
The oncologist 2012;17(4):492-8
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M
Annals of oncology : official journal of the European Society for Medical Oncology 2012 May;23(5):1144-1150
Annals of oncology : official journal of the European Society for Medical Oncology 2012 May;23(5):1144-1150
NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity.
Manandhar S, Choi BH, Jung KA, Ryoo IG, Song M, Kang SJ, Choi HG, Kim JA, Park PH, Kwak MK
Free radical biology & medicine 2012 May 1;52(9):1773-85
Free radical biology & medicine 2012 May 1;52(9):1773-85
Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases.
Yigit S, Pehlivan FS, Evcim G, Etit D
Pathology, research and practice 2012 Mar 15;208(3):147-50
Pathology, research and practice 2012 Mar 15;208(3):147-50
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF, Polydorides AD
Archives of pathology & laboratory medicine 2012 Jun;136(6):691-7
Archives of pathology & laboratory medicine 2012 Jun;136(6):691-7
SGK3 is associated with estrogen receptor expression in breast cancer.
Xu J, Wan M, He Q, Bassett RL Jr, Fu X, Chen AC, Shi F, Creighton CJ, Schiff R, Huo L, Liu D
Breast cancer research and treatment 2012 Jul;134(2):531-41
Breast cancer research and treatment 2012 Jul;134(2):531-41
Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
El-Gendi SM, Mostafa MF, El-Gendi AM
Pathology oncology research : POR 2012 Apr;18(2):459-69
Pathology oncology research : POR 2012 Apr;18(2):459-69
Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival.
Ege CB, Akbulut M, Zekioğlu O, Ozdemir N
Archives of gynecology and obstetrics 2011 Nov;284(5):1231-9
Archives of gynecology and obstetrics 2011 Nov;284(5):1231-9
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype.
Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang X, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A, Woodward WA
European journal of cancer (Oxford, England : 1990) 2011 Jul;47(10):1527-36
European journal of cancer (Oxford, England : 1990) 2011 Jul;47(10):1527-36
Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
Fernand VE, Losso JN, Truax RE, Villar EE, Bwambok DK, Fakayode SO, Lowry M, Warner IM
Chemico-biological interactions 2011 Jul 15;192(3):220-32
Chemico-biological interactions 2011 Jul 15;192(3):220-32
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast.
Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF
Cancer 2011 Jan 1;117(1):39-47
Cancer 2011 Jan 1;117(1):39-47
Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E, El-Gendi SM, Yehya A, Gowil AG
British journal of neurosurgery 2011 Dec;25(6):707-13
British journal of neurosurgery 2011 Dec;25(6):707-13
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.
Rygiel AM, Milano F, Ten Kate FJ, Bergman JJ, Krishnadath KK
Journal of oncology 2010;2010:382582
Journal of oncology 2010;2010:382582
Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine.
Fisher RD, Ultsch M, Lingel A, Schaefer G, Shao L, Birtalan S, Sidhu SS, Eigenbrot C
Journal of molecular biology 2010 Sep 10;402(1):217-29
Journal of molecular biology 2010 Sep 10;402(1):217-29
HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.
Bollig-Fischer A, Dziubinski M, Boyer A, Haddad R, Giroux CN, Ethier SP
Cancer research 2010 Oct 15;70(20):7862-73
Cancer research 2010 Oct 15;70(20):7862-73
Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling.
Pfister AB, Wood RC, Salas PJ, Zea DL, Ramsauer VP
Journal of cellular biochemistry 2010 Oct 15;111(3):643-52
Journal of cellular biochemistry 2010 Oct 15;111(3):643-52
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R
Journal of translational medicine 2010 Jun 7;8:53
Journal of translational medicine 2010 Jun 7;8:53
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A
Cancer 2010 Jul 15;116(14):3330-7
Cancer 2010 Jul 15;116(14):3330-7
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.
Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Naora H, Auersperg N, Mills GB, Bast RC, Liu J
Cell cycle (Georgetown, Tex.) 2010 Jan 1;9(1):140-6
Cell cycle (Georgetown, Tex.) 2010 Jan 1;9(1):140-6
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.
Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Naora H, Auersperg N, Mills GB, Bast RC, Liu J
Cell cycle (Georgetown, Tex.) 2010 Jan 1;9(1):140-6
Cell cycle (Georgetown, Tex.) 2010 Jan 1;9(1):140-6
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA
American journal of clinical pathology 2010 Aug;134(2):303-11
American journal of clinical pathology 2010 Aug;134(2):303-11
GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.
Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M
Breast cancer research and treatment 2010 Aug;123(1):51-8
Breast cancer research and treatment 2010 Aug;123(1):51-8
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, Huang W, Leitzel K, Weidler J, Ali SM, Fuchs EM, Singer CF, Köstler WJ, Bates M, Parry G, Winslow J, Lipton A
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Aug 15;16(16):4226-35
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Aug 15;16(16):4226-35
Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
Wang F, Ren J, Qiu XC, Wang LF, Zhu Q, Zhang YQ, Huan Y, Meng YL, Yao LB, Chen SY, Xu YM, Yang AG
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 15;16(8):2284-94
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 15;16(8):2284-94
Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.
Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 15;16(8):2266-74
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 15;16(8):2266-74
Immunohistochemical characterization of subtypes of male breast carcinoma.
Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y, Guo M
Breast cancer research : BCR 2009;11(3):R28
Breast cancer research : BCR 2009;11(3):R28
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Misirlioglu D, Nak D, Ozyigit MO, Nak Y, Akkoc A
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy.
Liu X, Wu J, Zhang S, Li C, Huang Q
Cancer gene therapy 2009 Nov;16(11):861-72
Cancer gene therapy 2009 Nov;16(11):861-72
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
Gilcrease MZ, Woodward WA, Nicolas MM, Corley LJ, Fuller GN, Esteva FJ, Tucker SL, Buchholz TA
The American journal of surgical pathology 2009 May;33(5):759-67
The American journal of surgical pathology 2009 May;33(5):759-67
Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
Middleton LP, Price KM, Puig P, Heydon LJ, Tarco E, Sneige N, Barr K, Deavers MT
Archives of pathology & laboratory medicine 2009 May;133(5):775-80
Archives of pathology & laboratory medicine 2009 May;133(5):775-80
A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S, Tahir H, Larson J, Goodman L, Whitcomb J, Petropoulos C, Winslow J
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2009 Mar;18(1):11-21
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2009 Mar;18(1):11-21
Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.
Strumane K, Rygiel T, van der Valk M, Collard JG
Journal of cancer research and clinical oncology 2009 Jan;135(1):69-80
Journal of cancer research and clinical oncology 2009 Jan;135(1):69-80
Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH
Molecular cancer research : MCR 2009 Feb;7(2):275-84
Molecular cancer research : MCR 2009 Feb;7(2):275-84
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, Lampin A, Niwa-Kawakita M, Kalamarides M, Giovannini M
Oncogene 2009 Feb 12;28(6):854-65
Oncogene 2009 Feb 12;28(6):854-65
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Gong Y, Sweet W, Duh YJ, Greenfield L, Tarco E, Trivedi S, Symmans WF, Isola J, Sneige N
American journal of clinical pathology 2009 Aug;132(2):228-36
American journal of clinical pathology 2009 Aug;132(2):228-36
Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.
Ren XL, Xu YM, Bao W, Fu HJ, Wu CG, Zhao Y, Li ZK, Zhang J, Li SQ, Chen WQ, Wang T, Zhang R, Zhang LH, Qian GS, Chen SY, Jia LT, Yang AG
Cancer letters 2009 Aug 28;281(2):134-43
Cancer letters 2009 Aug 28;281(2):134-43
Leptin augments proliferation of breast cancer cells via transactivation of HER2.
Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H
The Journal of surgical research 2008 Sep;149(1):9-14
The Journal of surgical research 2008 Sep;149(1):9-14
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
Van Schaeybroeck S, Kelly DM, Kyula J, Stokesberry S, Fennell DA, Johnston PG, Longley DB
Cancer research 2008 Oct 15;68(20):8312-21
Cancer research 2008 Oct 15;68(20):8312-21
Prognostic significance of HER-2 status in women with inflammatory breast cancer.
Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Inflammatory Breast Cancer Research Group
Cancer 2008 May 1;112(9):1905-11
Cancer 2008 May 1;112(9):1905-11
Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent.
Pedersen NM, Madshus IH, Haslekås C, Stang E
Molecular cancer research : MCR 2008 Mar;6(3):491-500
Molecular cancer research : MCR 2008 Mar;6(3):491-500
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L
Breast cancer research and treatment 2008 Mar;108(2):183-90
Breast cancer research and treatment 2008 Mar;108(2):183-90
Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.
Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J
Oncogene 2008 Jul 24;27(32):4434-45
Oncogene 2008 Jul 24;27(32):4434-45
Lipid raft localization of ErbB2 in vestibular schwannoma and schwann cells.
Brown KD, Hansen MR
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2008 Jan;29(1):79-85
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2008 Jan;29(1):79-85
Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44.
Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar VB
Cancer research 2008 Jan 15;68(2):483-91
Cancer research 2008 Jan 15;68(2):483-91
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, Teng M, Liu J
Proteins 2008 Feb 15;70(3):938-49
Proteins 2008 Feb 15;70(3):938-49
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
Dilworth JT, Wojtkowiak JW, Mathieu P, Tainsky MA, Reiners JJ Jr, Mattingly RR, Hancock CN
Cancer biology & therapy 2008 Dec;7(12):1938-46
Cancer biology & therapy 2008 Dec;7(12):1938-46
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
Dilworth JT, Wojtkowiak JW, Mathieu P, Tainsky MA, Reiners JJ Jr, Mattingly RR, Hancock CN
Cancer biology & therapy 2008 Dec;7(12):1938-46
Cancer biology & therapy 2008 Dec;7(12):1938-46
Loss of annexin A1 expression in breast cancer progression.
Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):530-4
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):530-4
Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF.
Kiley SC, Chevalier RL
American journal of physiology. Renal physiology 2007 Sep;293(3):F895-903
American journal of physiology. Renal physiology 2007 Sep;293(3):F895-903
Primary neuroendocrine carcinoma of the breast: a case report.
Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E
Tumori 2007 Sep-Oct;93(5):496-8
Tumori 2007 Sep-Oct;93(5):496-8
Primary neuroendocrine carcinoma of the breast: a case report.
Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E
Tumori 2007 Sep-Oct;93(5):496-8
Tumori 2007 Sep-Oct;93(5):496-8
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF
The Lancet. Oncology 2007 Mar;8(3):203-11
The Lancet. Oncology 2007 Mar;8(3):203-11
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer.
Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, Cristofanilli M
Annals of oncology : official journal of the European Society for Medical Oncology 2007 Jun;18(6):1021-9
Annals of oncology : official journal of the European Society for Medical Oncology 2007 Jun;18(6):1021-9
Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.
Half E, Sun Y, Sinicrope FA
Cancer letters 2007 Jun 28;251(2):237-46
Cancer letters 2007 Jun 28;251(2):237-46
Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications.
Nash JW, Barrett TL, Kies M, Ross MI, Sneige N, Diwan AH, Lazar AJ
Journal of cutaneous pathology 2007 Jan;34(1):49-54
Journal of cutaneous pathology 2007 Jan;34(1):49-54
An acetylation site in the middle domain of Hsp90 regulates chaperone function.
Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, Rosen N, Neckers L
Molecular cell 2007 Jan 12;25(1):151-9
Molecular cell 2007 Jan 12;25(1):151-9
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M
Cancer 2007 Feb 1;109(3):496-501
Cancer 2007 Feb 1;109(3):496-501
Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis.
Vairaktaris E, Moulavassili P, Loukeri S, Spyridonidou S, Yapijakis C, Vassiliou S, Nkenke E, Vylliotis A, Papakosta V, Lazaris A, Patsouris E
Journal of musculoskeletal & neuronal interactions 2007 Apr-Jun;7(2):185-90
Journal of musculoskeletal & neuronal interactions 2007 Apr-Jun;7(2):185-90
[An analysis of genetic transmission in a father and son with osteosarcoma].
Tokatli F, Alas RC, Altaner S, Pala F, Uygun K, Uzal C, Yalniz E
Acta orthopaedica et traumatologica turcica 2006;40(5):407-10
Acta orthopaedica et traumatologica turcica 2006;40(5):407-10
MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC).
Karg A, Dinç ZA, Başok O, Uçvet A
Pathology, research and practice 2006;202(8):577-83
Pathology, research and practice 2006;202(8):577-83
Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2.
Ramsauer VP, Pino V, Farooq A, Carothers Carraway CA, Salas PJ, Carraway KL
Molecular biology of the cell 2006 Jul;17(7):2931-41
Molecular biology of the cell 2006 Jul;17(7):2931-41
Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker.
Skálová A, Gnepp DR, Simpson RH, Lewis JE, Janssen D, Sima R, Vanecek T, Di Palma S, Michal M
The American journal of surgical pathology 2006 Aug;30(8):939-44
The American journal of surgical pathology 2006 Aug;30(8):939-44
Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker.
Skálová A, Gnepp DR, Simpson RH, Lewis JE, Janssen D, Sima R, Vanecek T, Di Palma S, Michal M
The American journal of surgical pathology 2006 Aug;30(8):939-44
The American journal of surgical pathology 2006 Aug;30(8):939-44
Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
Hansen MR, Roehm PC, Chatterjee P, Green SH
Glia 2006 Apr 15;53(6):593-600
Glia 2006 Apr 15;53(6):593-600
Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, O Yildirim E, Aktas E, Bilgic S, Kiran B, Deniz G, Price JE
Clinical & experimental metastasis 2005;22(1):39-46
Clinical & experimental metastasis 2005;22(1):39-46
Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer.
Diaz LK, Cristofanilli M, Zhou X, Welch KL, Smith TL, Yang Y, Sneige N, Sahin AA, Gilcrease MZ
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005 Sep;18(9):1165-75
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005 Sep;18(9):1165-75
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Oct 15;11(20):7480-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Oct 15;11(20):7480-9
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L
Cancer research 2005 Nov 15;65(22):10524-35
Cancer research 2005 Nov 15;65(22):10524-35
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT, Metz MZ, Kane SE
Breast cancer research and treatment 2005 May;91(2):187-201
Breast cancer research and treatment 2005 May;91(2):187-201
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 May 1;11(9):3309-14
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 May 1;11(9):3309-14
Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases.
Skalova A, Ryska A, Kajo K, Di Palma S, Kinkor Z, Michal M
Histopathology 2005 Jan;46(1):43-9
Histopathology 2005 Jan;46(1):43-9
Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry.
Di Palma S, Skálová A, Vanìèek T, Simpson RH, Stárek I, Leivo I
Histopathology 2005 Feb;46(2):144-52
Histopathology 2005 Feb;46(2):144-52
Decorin prevents metastatic spreading of breast cancer.
Reed CC, Waterhouse A, Kirby S, Kay P, Owens RT, McQuillan DJ, Iozzo RV
Oncogene 2005 Feb 3;24(6):1104-10
Oncogene 2005 Feb 3;24(6):1104-10
Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells.
Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, Watanabe T, Nagawa H
Biochemical and biophysical research communications 2005 Feb 18;327(3):907-14
Biochemical and biophysical research communications 2005 Feb 18;327(3):907-14
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.
Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L
Endocrine-related cancer 2005 Dec;12(4):1059-69
Endocrine-related cancer 2005 Dec;12(4):1059-69
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
Woods Ignatoski KM, Dziubinski ML, Ammerman C, Ethier SP
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
Woods Ignatoski KM, Dziubinski ML, Ammerman C, Ethier SP
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Aug 15;11(16):5686-93
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Aug 15;11(16):5686-93
Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.
Price-Schiavi SA, Andrechek E, Idris N, Li P, Rong M, Zhang J, Carothers Carraway CA, Muller WJ, Carraway KL
Journal of cellular physiology 2005 Apr;203(1):44-53
Journal of cellular physiology 2005 Apr;203(1):44-53
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2.
Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, Ali-Seyed M, Lee DF, Bartholomeusz G, Ou-Yang F, Giri DK, Hung MC
Cancer cell 2004 Sep;6(3):251-61
Cancer cell 2004 Sep;6(3):251-61
Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK.
Kansra S, Stoll SW, Johnson JL, Elder JT
Molecular biology of the cell 2004 Sep;15(9):4299-309
Molecular biology of the cell 2004 Sep;15(9):4299-309
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP
Gynecologic oncology 2004 Jan;92(1):160-6
Gynecologic oncology 2004 Jan;92(1):160-6
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP
Gynecologic oncology 2004 Jan;92(1):160-6
Gynecologic oncology 2004 Jan;92(1):160-6
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Gossett DR, Alo P, Bristow RE, Galati M, Kyshtoobayeva A, Fruehauf J, Montz FJ
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Gossett DR, Alo P, Bristow RE, Galati M, Kyshtoobayeva A, Fruehauf J, Montz FJ
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr, Liu J
The Journal of biological chemistry 2004 Feb 6;279(6):4339-45
The Journal of biological chemistry 2004 Feb 6;279(6):4339-45
HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors.
Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA
International journal of cancer 2004 Feb 10;108(4):540-8
International journal of cancer 2004 Feb 10;108(4):540-8
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS
Cancer 2004 Feb 1;100(3):499-506
Cancer 2004 Feb 1;100(3):499-506
Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures.
Zhang L, Fletcher-Turner A, Marchionni MA, Apparsundaram S, Lundgren KH, Yurek DM, Seroogy KB
Journal of neurochemistry 2004 Dec;91(6):1358-68
Journal of neurochemistry 2004 Dec;91(6):1358-68
Role of ErbB2 in Corneal Epithelial Wound Healing.
Xu KP, Riggs A, Ding Y, Yu FS
Investigative ophthalmology & visual science 2004 Dec;45(12):4277-83
Investigative ophthalmology & visual science 2004 Dec;45(12):4277-83
Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A
Cancer 2003 Sep 1;98(5):1055-60
Cancer 2003 Sep 1;98(5):1055-60
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Nov 15;9(15):5652-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Nov 15;9(15):5652-9
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R
FEBS letters 2003 May 22;543(1-3):76-80
FEBS letters 2003 May 22;543(1-3):76-80
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R
FEBS letters 2003 May 22;543(1-3):76-80
FEBS letters 2003 May 22;543(1-3):76-80
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Mar;9(3):955-60
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Mar;9(3):955-60
MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions.
Talukder AH, Mishra SK, Mandal M, Balasenthil S, Mehta S, Sahin AA, Barnes CJ, Kumar R
The Journal of biological chemistry 2003 Mar 28;278(13):11676-85
The Journal of biological chemistry 2003 Mar 28;278(13):11676-85
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Feb;9(2):845-52
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Feb;9(2):845-52
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Shimizu H, Seiki T, Asada M, Yoshimatsu K, Koyama N
Oncogene 2003 Feb 13;22(6):831-9
Oncogene 2003 Feb 13;22(6):831-9
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Simpson RH, Prasad AR, Lewis JE, Skálová A, David L
The American journal of surgical pathology 2003 Aug;27(8):1070-9
The American journal of surgical pathology 2003 Aug;27(8):1070-9
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Simpson RH, Prasad AR, Lewis JE, Skálová A, David L
The American journal of surgical pathology 2003 Aug;27(8):1070-9
The American journal of surgical pathology 2003 Aug;27(8):1070-9
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells.
Ramsauer VP, Carraway CA, Salas PJ, Carraway KL
The Journal of biological chemistry 2003 Aug 8;278(32):30142-7
The Journal of biological chemistry 2003 Aug 8;278(32):30142-7
Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.
Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G, Mikuz G, Ensinger C
Virchows Archiv : an international journal of pathology 2003 Apr;442(4):322-8
Virchows Archiv : an international journal of pathology 2003 Apr;442(4):322-8
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA
Cancer research 2002 Mar 15;62(6):1676-81
Cancer research 2002 Mar 15;62(6):1676-81
Metalloproteinases stimulate ErbB-dependent ERK signaling in human skin organ culture.
Stoll SW, Kansra S, Elder JT
The Journal of biological chemistry 2002 Jul 26;277(30):26839-45
The Journal of biological chemistry 2002 Jul 26;277(30):26839-45
Differential cytoskeletal association of ErbB1 and ErbB2 during keratinocyte differentiation.
Kansra S, Stoll SW, Elder JT
Biochemical and biophysical research communications 2002 Aug 2;295(5):1108-17
Biochemical and biophysical research communications 2002 Aug 2;295(5):1108-17
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Apr 1;20(7):1800-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Apr 1;20(7):1800-8
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Apr 1;20(7):1800-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Apr 1;20(7):1800-8
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
Murillo H, Schmidt LJ, Tindall DJ
Cancer research 2001 Oct 15;61(20):7408-12
Cancer research 2001 Oct 15;61(20):7408-12
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G, Lin PS, Contessa JN, Hampton JL, Valerie K, Schmidt-Ullrich RK
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G, Lin PS, Contessa JN, Hampton JL, Valerie K, Schmidt-Ullrich RK
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
Stoll SW, Kansra S, Peshick S, Fry DW, Leopold WR, Wiesen JF, Sibilia M, Zhang T, Werb Z, Derynck R, Wagner EF, Elder JT
Neoplasia (New York, N.Y.) 2001 Jul-Aug;3(4):339-50
Neoplasia (New York, N.Y.) 2001 Jul-Aug;3(4):339-50
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot of HER-2 using HER-2 Monoclonal Antibody (Product # MA5-13105) on SKBR3 Cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on membrane enriched extracts (30 µg lysate) of SK-BR-3 (1), T-47D (2) and MDA-MB-231 (3). The blot was probed with anti-ErbB2 Mouse Monoclonal Antibody (Product # MA5-13105, 1 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.25 µg/mL, 1:4000 dilution). A 185 kDa band corresponding to ErbB2 was observed in SK-BR-3 and moderate in T-47D where as it was not observed in MDA-MB-231 which is an ErbB2 negative cell line. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane using the wet transfer system. The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on membrane enriched extracts (30 µg lysate) of SK-BR-3 (1), T-47D (2) and MDA-MB-231 (3). The blot was probed with anti-ErbB2 Mouse Monoclonal Antibody (Product # MA5-13105, 1 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.25 µg/mL, 1:4000 dilution). A 185 kDa band corresponding to ErbB2 was observed in SK-BR-3 and moderate in T-47D where as it was not observed in MDA-MB-231 which is an ErbB2 negative cell line. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane using the wet transfer system. The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human breast carcinoma stained with c-erbB-2 antibody using peroxidase-conjugate and AEC chromogen. Note intense cell membrane staining of tumor cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of HER-2 showing staining in the cytoplasm and membrane of paraffin-embedded human breast carcinoma (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a HER-2 monoclonal antibody (Product # MA5-13105) diluted in 3% BSA-PBS at a dilution of 1:20 overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of HER-2 in MDA-MB-453 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with a HER-2 monoclonal antibody (Product # MA5-13105) at a dilution of 1 µg/test for 40 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of HER-2 in SK-BR-3 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with a HER-2 monoclonal antibody (Product # MA5-13105) at a dilution of 1 µg/test for 40 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of HER-2 using HER-2 Monoclonal Antibody (Product # MA5-13105) on denatured Human SKBR3 Cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 Nf1 deficiency induces ER + /PR + mammary tumors. We observed mammary tumors with diverse mammary histology in G0 - G2 animals. a Nf1 females and b Nf1 males developed mammary adenocarcinomas with mixed histology including acinar, cystic, papillary, ductal, and solid features. All images were taken at 100X magnification. c Immunostaining of Nf1 mammary tumors ( rNf1 #6) for estrogen receptor, progesterone receptor, HER2, Ki67, and pan-cytokeratin (AE1/AE3). All immunostaining images were taken at 200X magnification
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 T-DM1 increases VSVDelta51 activity in a panel of HER2-expressing breast and ovarian cancer lines. a A panel of human breast and ovarian carcinoma lines were lysed and subject to western blotting for human HER2. b Mouse breast carcinoma 4T1 cells, and a panel of human cancer cell lines were subject to extracellular staining with Herceptin(r), followed by goat anti-human IgG-PE. PE signal ( y axis) was analyzed by flow cytometry, median MFI are shown; n = 3 +- SD. c 786-0 and JIMT1 cells were pretreated with T-DM1 for 4 h, washed and infected with VSVDelta51 (MOI 0.05 and 0.01, respectively) and plaque assay performed 45 h later ( n = 3; mean +- SEM; one-way ANOVA with Dunnett's multiple comparisons test compared to 0 µg/mL T-DM1 for each cell line). d Indicated cell lines were pretreated with either 100 nM colchicine, 100 mug/mL T-DM1 or trastuzumab, or mock, for 3 h, then washed and infected with VSVDelta51 (MOI 0.01 for JIMT1 and MOI 0.001 for others). 1 h later, wells were overlayed with agarose, and plaques visualized with Coomassie blue 48 h later. Diameter of 30 plaques per well were graphed (mean +- SEM; one-way ANOVA with Dunnett's multiple comparisons test compared to Mock for each cell line). e JIMT1 cells were plated on glass coverslips, treated with 100 µg/mL T-DM1 or trastuzumab, or mock-treated, then stained for beta-tubulin and DAPI 24 h later. Objective = x63, scale bar = 50 um, n = 3. White arrow indicates polynuclear cells. f Cell lines in
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 T-DM1 increases oncolytic activity of VSVDelta51 in vivo and in human patient samples. a BALB/c nude mice were implanted with 1 x 10 7 JIMT1 cells. Once tumors were ~100 mm 3 , mice were treated weekly four times (dotted lines) with the regimen of VSVDelta51-Fluc (1E8 pfu) or PBS (intratumorally) followed by 10 mg/kg T-DM1 (Kadcyla(r)) or PBS 4 h later (intravenously). Survival was monitored over time ( n = 16-20 mice per group as indicated, pooled over three independent experiments) and was observed to be significantly reduced with the combination of VSVDelta51 + T-DM1 compared to either monotherapies ( p = 0.039 compared to Kadcyla; p = 0.004 compared to VSV; p < 0.0001 compared to PBS, Gehan-Breslow-Wilcoxon test). b Ascites fluid cells derived from three different human ovarian cancer patients were each lysed and blotted for HER2 or actin as a loading control. c Mouse breast carcinoma 4T1 cells, and the ascites fluid-derived cell lines were subject to extracellular staining and flow cytometry. Cells were stained with Herceptin(r) (trastuzumab, 1:1000), followed by goat anti-human IgG-PE (1:100). PE signal ( y axis) was analyzed by flow cytometry, median MFI are shown; n = 3 +- SD. d AF2028 and AF2068 were plated on glass coverslips, treated with 100 µg/mL T-DM1 or trastuzumab, then fixed and stained for beta-tubulin and DAPI 24 h later. Objective = x63, scale bar = 50 um, n = 3. White arrow indicates polynuclear cells. e The ascites fluid-derived cell lines w
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 MLH1 loss in ER + , nominally HER2 - breast cancer cells upregulates membrane-bound HER2. A Western blots demonstrating increase in pHER2 and downstream signaling in sh MLH1 MCF7 cells treated with fulvestrant relative to sh Luc cells. Quantification of four independent replicates conducted through ImageJ in accompanying dot plots. Validation in T47D cells in Fig. S3A . Immunofluorescent staining for HER2 in MCF7 sh Luc and sh MLH1 cells in vitro ( B ), in MCF7 sh Luc and sh MLH1 xenograft tumors ( C ), and in WHIM20, PMS2 mutant, ER + /HER2 - PDX tumors ( D ), grown with or without fulvestrant. Accompanying quantification presented as strip charts. Three independent experiments or tumors from each group were quantified. Two-sided Student's t test determined p values. Supporting data from FACS analysis are presented in Fig. S3B, C . Scale bars represent 50 u. Source data for all figures available with paper.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 MLH1 regulates protein trafficking of HER2. A Gene set enrichment analysis of RNAseq data comparing isogenic sh Luc and sh MLH1 MCF7 cells after treatment with fulvestrant for 4 days. P values were generated using DESeq2 R package and adjusted for multiple comparison using Benjamini-Hochberg. Comparable RPPA data analysis in Fig. S4A . Raw read counts available as supplementary data. B Co-immunofluorescence for HER2 and lysosomal marker, LAMP1 (orange arrows) at baseline and after 18, 36, and 54 h of fulvestrant treatment. Green arrows indicate HER2 that is not colocalized with LAMP1, and red arrows indicate LAMP1 positivity alone. Validation in T47D cells in Fig. S4B . C Immunofluorescence staining for HER2 in MCF7 sh Luc and sh MLH1 cells treated with vehicle and 36 h of fulvestrant alone or a combination of fulvestrant and chloroquine, an autophagy inhibitor. For sh Luc vs. sh MLH1 vehicle, p = 0.0006. Validation in T47D cells in Fig. S4C . Quantification ( D ) and representative photomicrographs ( E ) from 36 h of live cell tracking of colocalization of HER2 and LC3 (orange arrows), a marker of autophagosomes, in MCF7 sh Luc and sh MLH1 cells treated with vehicle or fulvestrant. Green arrows indicate HER2 + LC3 - cells. Cells were tracked after administration of fulvestrant. All quantification is of three independent biological replicates conducted through ImageJ and is represented as strip charts. Two-sided Student's t test determined all p values. For sh Luc vehi
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 10 Immunohistochemical staining of the xenograft tumor sections (400X). Dark brown color was observed as positive staining. Tissues from xenograft tumors were negative for ER (A) , PR (B) and HER-2 (C) , and were positive for P63 (D) , CK5/6 (E) , and alpha-SMA (F) localized in the cell membrane.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 The rare-cell sc WB measures 12 unique protein targets in single cells from three cancer subtypes. ( a ) Fluorescence micrographs and intensity plots from rare-cell sc WB handling and analysis of healthy blood samples, each spiked with a cancer subtype: EGFR+(BT-20), ER+(MCF7) and HER2+(SK-BR-3). Negative controls include analysis of WBCs only and blank microwells (that is, devoid of a cancer cell). Protein panel comprises the following: control and housekeeping proteins (GAPDH and beta-tubulin), oncoproteins (HER2, ER and EGFR), signalling proteins (ERK, eIF4E and mTOR), common CTC classifiers (EpCAM, panCK and CK8) and a WBC indicator (CD45). Scale bar, 50 mum. ( b ) Comparative protein expression for each cancer cell (BT-20: n =27; SK-BR-3: n =27; MCF7: n =35), with mean and CV noted for each marker. Protein expression is graphed using a log-scale. Ranked oncoprotein expression for each cell line agrees with cancer subtype. Less than 1% of total protein signal is attributable to CD45.